AT190354T - Control of gene expression by ionizing radiation - Google Patents

Control of gene expression by ionizing radiation

Info

Publication number
AT190354T
AT190354T AT92903431T AT92903431T AT190354T AT 190354 T AT190354 T AT 190354T AT 92903431 T AT92903431 T AT 92903431T AT 92903431 T AT92903431 T AT 92903431T AT 190354 T AT190354 T AT 190354T
Authority
AT
Austria
Prior art keywords
control
gene expression
ionizing radiation
ionizing
radiation
Prior art date
Application number
AT92903431T
Other languages
German (de)
Inventor
Ralph R Weichselbaum
Dennis E Hallahan
Vikas P Sukhatme
Donald W Kufe
Original Assignee
Arch Dev Corp The University O
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US63362690A priority Critical
Application filed by Arch Dev Corp The University O, Dana Farber Cancer Inst Inc filed Critical Arch Dev Corp The University O
Priority to PCT/US1991/009651 priority patent/WO1992011033A1/en
Publication of AT190354T publication Critical patent/AT190354T/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation; Therapies using these preparations
    • A61K41/0023Agression treatment or altering
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/525Tumour necrosis factor [TNF]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67General methods for enhancing the expression
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
AT92903431T 1990-12-20 1991-12-19 Control of gene expression by ionizing radiation AT190354T (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US63362690A true 1990-12-20 1990-12-20
PCT/US1991/009651 WO1992011033A1 (en) 1990-12-20 1991-12-19 Control of gene expression by ionizing radiation

Publications (1)

Publication Number Publication Date
AT190354T true AT190354T (en) 2000-03-15

Family

ID=24540424

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92903431T AT190354T (en) 1990-12-20 1991-12-19 Control of gene expression by ionizing radiation

Country Status (10)

Country Link
US (2) US5612318A (en)
EP (1) EP0563278B1 (en)
JP (1) JP3337214B2 (en)
AT (1) AT190354T (en)
AU (1) AU657111B2 (en)
CA (1) CA2098849C (en)
DE (2) DE69132031T2 (en)
DK (1) DK0563278T3 (en)
ES (1) ES2144414T3 (en)
WO (1) WO1992011033A1 (en)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922304A (en) 1989-12-22 1999-07-13 Imarx Pharmaceutical Corp. Gaseous precursor filled microspheres as magnetic resonance imaging contrast agents
US6088613A (en) 1989-12-22 2000-07-11 Imarx Pharmaceutical Corp. Method of magnetic resonance focused surgical and therapeutic ultrasound
US20020150539A1 (en) * 1989-12-22 2002-10-17 Unger Evan C. Ultrasound imaging and treatment
US6551576B1 (en) 1989-12-22 2003-04-22 Bristol-Myers Squibb Medical Imaging, Inc. Container with multi-phase composition for use in diagnostic and therapeutic applications
US7083572B2 (en) * 1993-11-30 2006-08-01 Bristol-Myers Squibb Medical Imaging, Inc. Therapeutic delivery systems
US6743779B1 (en) 1994-11-29 2004-06-01 Imarx Pharmaceutical Corp. Methods for delivering compounds into a cell
US5542935A (en) 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5776429A (en) 1989-12-22 1998-07-07 Imarx Pharmaceutical Corp. Method of preparing gas-filled microspheres using a lyophilized lipids
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US6605712B1 (en) * 1990-12-20 2003-08-12 Arch Development Corporation Gene transcription and ionizing radiation: methods and compositions
AT190354T (en) * 1990-12-20 2000-03-15 Arch Dev Corp The University O Control of gene expression by ionizing radiation
US5205290A (en) 1991-04-05 1993-04-27 Unger Evan C Low density microspheres and their use as contrast agents for computed tomography
US5874062A (en) 1991-04-05 1999-02-23 Imarx Pharmaceutical Corp. Methods of computed tomography using perfluorocarbon gaseous filled microspheres as contrast agents
AU692434B2 (en) * 1993-01-21 1998-06-11 President And Fellows Of Harvard College Methods and diagnostic kits utilizing mammalian stress promoters to determine toxicity of a compound
US8021667B2 (en) 1994-11-16 2011-09-20 Macfarlane Burnet Institute For Medical Research And Public Health Ltd Compositions for immunotherapy and uses thereof
AUPM322393A0 (en) * 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
US6548643B1 (en) 1994-11-16 2003-04-15 Austin Research Institute Antigen carbohydrate compounds and their use in immunotherapy
US7592317B1 (en) 1994-08-11 2009-09-22 The University Of Chicago Constitutive gene expression in conjuction with ionizing radiation
WO1997040679A1 (en) 1996-05-01 1997-11-06 Imarx Pharmaceutical Corp. Methods for delivering compounds into a cell
US5962424A (en) * 1995-02-21 1999-10-05 Arch Development Corporation Methods and compositions for targeting selectins
AU4994596A (en) * 1995-03-01 1996-09-18 Cornell Research Foundation Inc. Interdependent adenoviral vectors and methods of using same
US5997898A (en) 1995-06-06 1999-12-07 Imarx Pharmaceutical Corp. Stabilized compositions of fluorinated amphiphiles for methods of therapeutic delivery
US6521211B1 (en) 1995-06-07 2003-02-18 Bristol-Myers Squibb Medical Imaging, Inc. Methods of imaging and treatment with targeted compositions
US6231834B1 (en) 1995-06-07 2001-05-15 Imarx Pharmaceutical Corp. Methods for ultrasound imaging involving the use of a contrast agent and multiple images and processing of same
US6139819A (en) 1995-06-07 2000-10-31 Imarx Pharmaceutical Corp. Targeted contrast agents for diagnostic and therapeutic use
CA2191903A1 (en) * 1995-12-20 1997-06-21 Jun Ikeda Stress proteins
US6414139B1 (en) 1996-09-03 2002-07-02 Imarx Therapeutics, Inc. Silicon amphiphilic compounds and the use thereof
WO1998010798A1 (en) 1996-09-11 1998-03-19 Imarx Pharmaceutical Corp. Improved methods for diagnostic imaging using a contrast agent and a vasodilator
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
JP2001514658A (en) * 1997-03-10 2001-09-11 リサーチ ディベロップメント ファンデーション Temporary and selective photodynamic cause oxidative stress on expression treatment of heterologous genes
WO1998040508A1 (en) * 1997-03-14 1998-09-17 Selective Genetics, Inc. Adenoviral vectors with modified tropism
US6143276A (en) 1997-03-21 2000-11-07 Imarx Pharmaceutical Corp. Methods for delivering bioactive agents to regions of elevated temperatures
US6090800A (en) 1997-05-06 2000-07-18 Imarx Pharmaceutical Corp. Lipid soluble steroid prodrugs
US20050019266A1 (en) * 1997-05-06 2005-01-27 Unger Evan C. Novel targeted compositions for diagnostic and therapeutic use
US6416740B1 (en) 1997-05-13 2002-07-09 Bristol-Myers Squibb Medical Imaging, Inc. Acoustically active drug delivery systems
US6537246B1 (en) * 1997-06-18 2003-03-25 Imarx Therapeutics, Inc. Oxygen delivery agents and uses for the same
US6548047B1 (en) 1997-09-15 2003-04-15 Bristol-Myers Squibb Medical Imaging, Inc. Thermal preactivation of gaseous precursor filled compositions
DK1027063T3 (en) 1997-09-29 2009-06-02 Macfarlane Burnet Inst For Med Mannose receptor-bearing cell line and antigenic composition
CA2308606A1 (en) 1997-11-06 1999-05-20 Chiron S.P.A. Neisserial antigens
AU1390699A (en) * 1997-11-17 1999-06-07 Imarx Pharmaceutical Corp. A method of increasing nucleic acid synthesis with ultrasound
EP1034267A1 (en) * 1997-12-04 2000-09-13 Genzyme Corporation Compositions and methods for inducing gene expression
US6123923A (en) 1997-12-18 2000-09-26 Imarx Pharmaceutical Corp. Optoacoustic contrast agents and methods for their use
US20010003580A1 (en) 1998-01-14 2001-06-14 Poh K. Hui Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
BR9906927A (en) 1998-01-14 2001-11-20 Chiron Spa Neisseria meningitidis protein
AT376591T (en) 1998-05-01 2007-11-15 Novartis Vaccines & Diagnostic Neisseria meningitidis antigenic and assortments
US6380393B1 (en) 1999-03-19 2002-04-30 San Diego State University Foundation Ligands, transition metal complexes and methods of using same
EP1228217B1 (en) 1999-04-30 2012-11-21 Novartis Vaccines and Diagnostics S.r.l. Conserved neisserial antigens
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
EP1801219B1 (en) 1999-10-29 2015-10-14 GlaxoSmithKline Biologicals S.A. Neisserial antigenic peptides
JP2003516731A (en) 1999-11-18 2003-05-20 カイロン コーポレイション Human fgf-21 gene and gene expression products
JP2003520248A (en) 2000-01-17 2003-07-02 カイロン エセ.ピー.アー. N. Outer membrane vesicles containing meningitidis serotype b outer membrane protein (OMV) vaccines
EP1854476A3 (en) 2000-02-09 2008-05-07 Bas Medical, Inc. Use of relaxin to treat diseases related to vasoconstriction
EP2075255A1 (en) 2000-03-08 2009-07-01 Novartis Vaccines and Diagnostics, Inc. Human FGF-23 gene and gene expression products
AU6393801A (en) * 2000-05-23 2001-12-03 Warner Lambert Co Methods and compositions to activate genes in cells
EP1950297A2 (en) 2000-05-31 2008-07-30 Novartis Vaccines and Diagnostics, Inc. Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers
US7700359B2 (en) 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
JP5363695B2 (en) 2000-06-15 2013-12-11 ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド Polynucleotides related to colon cancer
US6579522B1 (en) 2000-06-27 2003-06-17 Genvec, Inc. Replication deficient adenoviral TNF vector
MX357775B (en) 2000-10-27 2018-07-20 J Craig Venter Inst Inc Nucleic acids and proteins from streptococcus groups a b.
AU2736502A (en) 2000-12-07 2002-06-18 Chiron Corp Endogenous retroviruses up-regulated in prostate cancer
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
US8034791B2 (en) 2001-04-06 2011-10-11 The University Of Chicago Activation of Egr-1 promoter by DNA damaging chemotherapeutics
WO2002081642A2 (en) 2001-04-06 2002-10-17 Georgetown University Gene brcc-3 and diagnostic and therapeutic uses thereof
US20030082685A1 (en) * 2001-04-06 2003-05-01 WEICHSELBAUM Ralph R. Chemotherapeutic induction of egr-1 promoter activity
AU2002303261A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene brcc2 and diagnostic and therapeutic uses thereof
AU2002305151A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene scc-112 and diagnostic and therapeutic uses thereof
JP3966819B2 (en) 2001-05-24 2007-08-29 キム,スーギョン The second keratinocyte growth factor analogs new present in the hair follicles
AU2004213452A1 (en) 2003-02-14 2004-09-02 Sagres Discovery, Inc. Therapeutic GPCR targets in cancer
US20030086903A1 (en) * 2001-11-02 2003-05-08 Genvec, Inc. Therapeutic regimen for treating cancer
NZ533428A (en) 2001-12-12 2008-03-28 Chiron Srl Immunisation against chlamydia trachomatis
EP2075346A3 (en) 2002-01-08 2009-11-11 Novartis Vaccines and Diagnostics, Inc. Gene products differentially expressed in cancerous breast cells and their methods of use
WO2003066066A1 (en) * 2002-02-01 2003-08-14 Vanderbilt University Targeted drug delivery methods
EP1501855A4 (en) 2002-03-21 2006-02-22 Sagres Discovery Inc Novel compositions and methods in cancer
US7138512B2 (en) 2002-04-10 2006-11-21 Georgetown University Gene SHINC-2 and diagnostic and therapeutic uses thereof
US7244565B2 (en) 2002-04-10 2007-07-17 Georgetown University Gene shinc-3 and diagnostic and therapeutic uses thereof
EP1532161B1 (en) 2002-06-13 2012-02-15 Novartis Vaccines and Diagnostics, Inc. Vectors for expression of hml-2 polypeptides
EP1562982B1 (en) 2002-11-15 2010-05-05 Novartis Vaccines and Diagnostics S.r.l. Unexpected surface proteins in neisseria meningitidis
US20040170982A1 (en) 2003-02-14 2004-09-02 Morris David W. Novel therapeutic targets in cancer
US20040242523A1 (en) * 2003-03-06 2004-12-02 Ana-Farber Cancer Institue And The Univiersity Of Chicago Chemo-inducible cancer gene therapy
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
US7767387B2 (en) 2003-06-13 2010-08-03 Sagres Discovery, Inc. Therapeutic targets in cancer
WO2005051432A1 (en) * 2003-11-14 2005-06-09 Genvec, Inc. Therapeutic regimen for treating cancer
ES2407465T3 (en) 2004-03-29 2013-06-12 Galpharma Co., Ltd. New modified galectin 9 protein and use thereof
US20060024677A1 (en) 2004-07-20 2006-02-02 Morris David W Novel therapeutic targets in cancer
CA2577550C (en) * 2004-08-25 2012-10-16 The University Of Chicago Use of the combination comprising temozolomide and tnf-alpha for treating glioblastoma
US7939490B2 (en) 2004-12-13 2011-05-10 University Of Maryland, Baltimore TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death
NZ560929A (en) 2005-02-18 2009-12-24 Novartis Vaccines & Diagnostic Immunogens from uropathogenic escherichia coli
AU2006235276A1 (en) 2005-04-07 2006-10-19 Novartis Vaccines And Diagnostics Inc. CACNA1E in cancer diagnosis, detection and treatment
EP1871911A2 (en) 2005-04-07 2008-01-02 Chiron Corporation Cancer-related genes (prlr)
CA2665080C (en) * 2005-10-01 2015-11-24 Charles Stout Regulatable fusion promoters
WO2009030978A2 (en) 2006-06-09 2009-03-12 Novartis Ag Conformers of bacterial adhesins
US20100166788A1 (en) 2006-08-16 2010-07-01 Novartis Vaccines And Diagnostics Immunogens from uropathogenic escherichia coli
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
EP2403526B1 (en) 2009-03-06 2019-05-15 GlaxoSmithKline Biologicals SA Chlamydia antigens
JP5830009B2 (en) 2009-04-14 2015-12-09 ノバルティス アーゲー Composition for immunizing against Staphylococcusaureus
JP2012532600A (en) 2009-07-07 2012-12-20 ノバルティス アーゲー Stored E. coli immunogen
EP2464658B1 (en) 2009-07-16 2014-10-01 Novartis AG Detoxified escherichia coli immunogens
US9605844B2 (en) * 2009-09-01 2017-03-28 Cree, Inc. Lighting device with heat dissipation elements
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4677063A (en) * 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
GB2170060B (en) * 1985-01-23 1988-12-21 Pirelli General Plc Improvements in or relating to electric cable joints
US5206152A (en) * 1988-04-08 1993-04-27 Arch Development Corporation Cloning and expression of early growth regulatory protein genes
AT190354T (en) * 1990-12-20 2000-03-15 Arch Dev Corp The University O Control of gene expression by ionizing radiation
US5571797A (en) * 1994-05-11 1996-11-05 Arch Development Corporation Method of inducing gene expression by ionizing radiation

Also Published As

Publication number Publication date
CA2098849A1 (en) 1992-06-21
WO1992011033A1 (en) 1992-07-09
CA2098849C (en) 2007-07-10
EP0563278A4 (en) 1994-02-02
US5612318A (en) 1997-03-18
DK0563278T3 (en) 2000-08-21
AU657111B2 (en) 1995-03-02
DE69132031T2 (en) 2000-07-13
JP3337214B2 (en) 2002-10-21
DE69132031D1 (en) 2000-04-13
EP0563278A1 (en) 1993-10-06
JPH06506194A (en) 1994-07-14
AU9170291A (en) 1992-07-22
EP0563278B1 (en) 2000-03-08
ES2144414T3 (en) 2000-06-16
US5817636A (en) 1998-10-06

Similar Documents

Publication Publication Date Title
DE69228528D1 (en) Ventricular Kanüliervorrichtung
DE59306034D1 (en) Photosensitive compositions
DE69122118T2 (en) inhaler
DE69127826D1 (en) inhaler
DE69122077D1 (en) Pacemaker
DE3278012D1 (en) Enclosure pressurisation control system
NO950852D0 (en) new connections
DE69132332T2 (en) Hepatitis C virus-epitope
DE69121105T2 (en) inhaler
DE3115593A1 (en) "Therapeutic uebungsvorrichtung"
DE69329465T2 (en) Griffel supporters computer
DE3043377A1 (en) atomizer
DE3114013A1 (en) fixing
DE69127342D1 (en) Treatment system by iontophoresis
FI915848A (en) By means of inhalering aktiverbar doseringsanordning.
NO914480L (en) Bridge Control
BR9008021A (en) Set of heating elements
DE69314450T2 (en) well cementing
AT152499T (en) spacer
DE69326184T2 (en) Radiation-sensitive compositions
FI933979A0 (en) Bioeroderbar an arrangement Foer dosering of aktiva ingredienser
DE69318306D1 (en) inhaler
DE69327695T2 (en) Pacemaker lead
DE69109754D1 (en) Fixing of biomolecules by increased Niederschlagelektrophorese.
DE69210440T2 (en) Charged particle beam arrangement

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee